Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry

J Gastroenterol Hepatol. 2022 Aug;37(8):1642-1644. doi: 10.1111/jgh.15918. Epub 2022 Jun 30.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoisobutyric Acids
  • Antiviral Agents / therapeutic use
  • Carbamates
  • Cyclopropanes
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C* / drug therapy
  • Hepatitis C* / epidemiology
  • Hepatitis C, Chronic* / drug therapy
  • Hepatitis C, Chronic* / epidemiology
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Humans
  • Lactams, Macrocyclic
  • Leucine / analogs & derivatives
  • Proline / analogs & derivatives
  • Quinoxalines
  • Registries
  • Sofosbuvir / therapeutic use
  • Sulfonamides
  • Treatment Outcome

Substances

  • Aminoisobutyric Acids
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Heterocyclic Compounds, 4 or More Rings
  • Lactams, Macrocyclic
  • Quinoxalines
  • Sulfonamides
  • voxilaprevir
  • Proline
  • Leucine
  • velpatasvir
  • Sofosbuvir